Cover Image

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

Objective: To explore whether the isocitrate dehydrogenase 1 (IDH1) or 1p/19q status determines the prognostic vs predictive role of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in the Neuro-Oncology Working Group of the German Cancer Society (NOA)-04 trial anaplastic glioma bi...

Full description

Saved in:
Bibliographic Details
Main Authors: Wick, Wolfgang (Author) , Meisner, Christoph (Author) , Hentschel, Bettina (Author) , Platten, Michael (Author) , Schilling, Alissa Maria (Author) , Wiestler, Benedikt (Author) , Sabel, Michael (Author) , Koeppen, Susanne (Author) , Ketter, Ralf (Author) , Weiler, Markus (Author) , Tabatabai, Ghazaleh (Author) , Deimling, Andreas von (Author) , Gramatzki, Dorothee (Author) , Westphal, Manfred (Author) , Schmitz-Schackert, Gabriele (Author) , Loeffler, Markus (Author) , Simon, Matthias (Author) , Reifenberger, Guido (Author) , Weller, Michael (Author)
Format: Article (Journal)
Language:English
Published: October 22, 2013
In: Neurology
Year: 2013, Volume: 81, Issue: 17, Pages: 1515-1522
ISSN:1526-632X
DOI:10.1212/WNL.0b013e3182a95680
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1212/WNL.0b013e3182a95680
Verlag, lizenzpflichtig, Volltext: https://n.neurology.org/content/81/17/1515
Get full text
Author Notes:Wolfgang Wick, Christoph Meisner, Bettina Hentschel, Michael Platten, Alissa Schilling, Benedikt Wiestler, Michael C. Sabel, Susanne Koeppen, Ralf Ketter, Markus Weiler, Ghazaleh Tabatabai, Andreas von Deimling, Dorothee Gramatzki, Manfred Westphal, Gabriele Schackert, Markus Loeffler, Matthias Simon, Guido Reifenberger, Michael Weller
Description
Summary:Objective: To explore whether the isocitrate dehydrogenase 1 (IDH1) or 1p/19q status determines the prognostic vs predictive role of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in the Neuro-Oncology Working Group of the German Cancer Society (NOA)-04 trial anaplastic glioma biomarker cohort. - Methods: Patients (n = 183) of the NOA-04 trial with known MGMT and IDH1 status were analyzed for interdependency of the prognostic vs predictive role of MGMT promoter methylation from IDH1 or 1p/19q status and treatment, using progression-free survival (PFS) as an endpoint. An independent validation cohort of the German Glioma Network (n = 75) and the NOA-08 trial (n = 34) served as a confirmation cohort. - Results: In tumors with IDH1 mutation, MGMT promoter methylation was associated with prolonged PFS with chemotherapy ± radiotherapy (RT) or RT-only groups, and is thus prognostic. In tumors without IDH1 mutation, MGMT promoter methylation was associated with increased PFS in patients treated with chemotherapy, but not in those who received RT alone as the first-line treatment, and is thus chemotherapy-predictive. In contrast, 1p/19q codeletions showed no such association with the prognostic vs predictive value of MGMT. - Conclusions: MGMT promoter methylation is a predictive biomarker for benefit from alkylating agent chemotherapy in patients with IDH1-wild-type, but not IDH1-mutant, malignant gliomas of World Health Organization grades III/IV. Combined IDH1/MGMT assessment may help to individualize clinical decision-making in neuro-oncology.
Item Description:Gesehen am 04.11.2021
Physical Description:Online Resource
ISSN:1526-632X
DOI:10.1212/WNL.0b013e3182a95680

Similar Items